Russian start-up takes its cancer drug candidate to US for clinical trials

Incuron, a three-year-old Russian biotech start-up, has been given the green light from the U.S.? FDA for a series of clinical trial testing in the States of its cancer drug candidate.

Incuron, a three-year-old Russian biotech start-up, announced earlier this week that it has been given the green light from the U.S.? FDA for a series of clinical trial testing in the States of its CBL0137 cancer drug candidate. ?We?re pleased to announce that we?re going to launch investigation of a new drug, CBL0137, in the USA. Now we?re holding clinical trials in Russia with a peroral form, and hope that the intravenous form-based trial in the USA will help us open new horizons?, said Andrey Leonov, the CEO of Incuron. He also added that ?during these initial US and Russia-based phases of clinical trials we hope to obtain additional information on how the CBL0137 influences the level of expression,? which will enable the start-up to ?effectively plan further clinical development of the candidate.? ?The FDA okaying the survey of an innovative molecule in the U.S. by a Russian start-up is an exceptional case among Russian companies,? said Vladimir Tezov, the CEO of Bioprocess Capital Partners LLP Managing Company which helped set up Incuron in 2010 in partnership with Russian Venture Company, VEB Bank, and Cleveland BioLabs, a US-based private investor...